CI vs ELV vs CVS
161 measures in 16 categories, one definition each, computed from filings and market data.
CI61.3
Cigna Corporation
Healthcare · Medical - Healthcare Plans
$302.30 +1.24%$79.9B mkt cap
Score DNA
ELV57.0
Elevance Health Inc.
Healthcare · Medical - Healthcare Plans
$428.26 −0.10%$92.9B mkt cap
Score DNA
CVS52.1
CVS Health Corp.
Healthcare · Medical - Healthcare Plans
$92.36 −0.24%$118.1B mkt cap
Score DNA
Price, rebased to 100 three years ago
CI ELV CVS · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | CI | ELV | CVS |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 3 | 0 |
| Insider $ bought, 180d | — | $1.37M | — |
| Congress purchases, 180d | 3 | 0 | 2 |
| Last Congress purchase | 2026-09-11 | — | 2026-06-02 |
| 13F net change in holders | +41 | — | +201 |
| ETFs adding shares, 30d | 1,436 | 464 | 1,369 |
| ETFs trimming, 30d | 1,155 | 442 | 1,138 |
| Net ETF funds, 30d | +281 | +22 | +231 |
Valuation
16 measures| Measure | CI | ELV | CVS |
|---|---|---|---|
| P/E (TTM) | 12.5x
0th
|
18.7x
29th
|
24.1x
57th
|
| PEG (P/E ÷ 3-yr EPS CAGR) | 4.75 | — | 1.28 |
| Price / sales | 0.3x
20th
|
0.5x
60th
|
0.3x
30th
|
| Price / book | 1.9x
20th
|
2.1x
30th
|
1.5x
0th
|
| Price / tangible book | — | 15.2x
88th
|
— |
| Price / free cash flow | 8.8x
33rd
|
14.8x
67th
|
10.0x
56th
|
| Price / operating cash flow | 7.8x
20th
|
12.4x
60th
|
8.0x
30th
|
| Enterprise value | $105.5B
80th
|
$86.4B
70th
|
$180.5B
90th
|
| EV / sales | 0.4x
50th
|
0.4x
60th
|
0.4x
70th
|
| EV / EBITDA | 8.5x
12th
|
10.5x
25th
|
13.5x
50th
|
| EV / EBIT | 10.7x
12th
|
12.4x
25th
|
20.3x
75th
|
| EV / free cash flow | 11.6x
44th
|
13.7x
56th
|
15.3x
67th
|
| Earnings yield | 8.0%
100th
|
5.3%
80th
|
4.2%
60th
|
| FCF yield | 11.4%
70th
|
6.8%
40th
|
10.0%
50th
|
| Operating cash flow yield | 12.9%
80th
|
8.0%
40th
|
12.5%
70th
|
| Graham number (per share) | $297.16
86th
|
$324.90
100th
|
$73.11
43rd
|
Profitability (TTM)
12 measures| Measure | CI | ELV | CVS |
|---|---|---|---|
| Gross margin | 11.7%
10th
|
39.0%
90th
|
14.2%
40th
|
| EBITDA margin | 4.4%
80th
|
4.1%
60th
|
3.2%
50th
|
| Operating margin | 3.5%
60th
|
3.5%
70th
|
2.0%
50th
|
| EBIT margin | 3.5%
70th
|
3.5%
60th
|
2.1%
50th
|
| Net margin | 2.3%
60th
|
2.5%
70th
|
1.2%
50th
|
| NOPAT margin | 2.8%
60th
|
3.0%
70th
|
1.7%
50th
|
| FCF margin | 3.2%
50th
|
3.1%
40th
|
2.8%
20th
|
| Operating cash flow margin | 3.6%
40th
|
3.7%
50th
|
3.6%
30th
|
| R&D / revenue | 0.0%
0th
|
0.0%
0th
|
0.0%
0th
|
| SG&A / revenue | 4.9%
40th
|
3.1%
20th
|
0.0%
0th
|
| Stock comp / revenue | 0.0%
0th
|
0.1%
30th
|
0.1%
10th
|
| Effective tax rate | 17.8%
50th
|
15.6%
30th
|
15.8%
40th
|
Returns on capital
11 measures| Measure | CI | ELV | CVS |
|---|---|---|---|
| ROE (on average equity) | 15.5%
60th
|
11.2%
50th
|
6.2%
30th
|
| ROA | 4.2%
70th
|
4.0%
60th
|
1.9%
30th
|
| ROIC | 11.8%
60th
|
15.5%
80th
|
4.9%
50th
|
| ROCE | 9.7%
70th
|
7.5%
50th
|
5.3%
30th
|
| Return on tangible assets | 6.4%
70th
|
5.6%
60th
|
3.5%
30th
|
| Cash ROIC (OCF / invested capital) | 15.1%
29th
|
19.4%
57th
|
10.4%
14th
|
| Gross profitability (GP / assets) | 21.0%
0th
|
62.0%
90th
|
23.1%
20th
|
| ROIC, 3-yr average | 7.5%
50th
|
16.1%
83rd
|
3.9%
33rd
|
| ROIC, 5-yr average | 8.3%
57th
|
21.8%
86th
|
4.2%
43rd
|
| ROE, 5-yr average | 12.6%
50th
|
14.6%
80th
|
7.3%
40th
|
| Incremental ROIC | 110.8%
80th
|
71.1%
40th
|
-77.2%
0th
|
Growth
17 measures| Measure | CI | ELV | CVS |
|---|---|---|---|
| Revenue growth (TTM YoY) | 7.7%
50th
|
6.3%
30th
|
7.4%
40th
|
| Revenue growth (QoQ) | 4.6%
60th
|
0.6%
20th
|
5.6%
80th
|
| Revenue CAGR, 3 yr | 14.9%
80th
|
6.7%
10th
|
7.0%
20th
|
| Revenue CAGR, 5 yr | 11.1%
40th
|
9.3%
10th
|
8.3%
0th
|
| Gross profit CAGR, 3 yr | 11.8%
60th
|
-22.1%
10th
|
2.7%
30th
|
| Operating income CAGR, 3 yr | 6.3%
67th
|
-5.4%
50th
|
9.1%
83rd
|
| Net income growth (TTM YoY) | 27.9%
80th
|
-7.4%
40th
|
8.3%
60th
|
| Net income CAGR, 3 yr | -1.3%
60th
|
-8.1%
40th
|
18.7%
100th
|
| EPS growth (TTM YoY) | 29.9%
80th
|
-4.0%
40th
|
7.2%
60th
|
| EPS CAGR, 3 yr | 2.6%
60th
|
-5.4%
40th
|
18.8%
80th
|
| EPS CAGR, 5 yr | 0.6%
40th
|
5.9%
100th
|
-6.8%
20th
|
| FCF growth (TTM YoY) | 131.1%
50th
|
17.8%
25th
|
146.0%
62nd
|
| FCF CAGR, 3 yr | -7.2%
33rd
|
-15.9%
11th
|
-12.7%
22nd
|
| Operating cash flow CAGR, 3 yr | -7.3%
40th
|
-14.2%
20th
|
-10.4%
30th
|
| Book value CAGR, 3 yr | 1.8%
20th
|
8.6%
80th
|
3.2%
40th
|
| Dividend CAGR, 3 yr | 4.8%
100th
|
2.6%
50th
|
0.4%
0th
|
| Sustainable growth rate | 11.6%
57th
|
7.8%
43rd
|
1.9%
0th
|
Margin history & stability
7 measures| Measure | CI | ELV | CVS |
|---|---|---|---|
| Gross margin, 3-yr average | 11.4%
10th
|
79.7%
90th
|
14.2%
40th
|
| Operating margin, 3-yr average | 3.7%
70th
|
4.1%
80th
|
2.6%
50th
|
| Net margin, 3-yr average | 2.0%
70th
|
3.1%
80th
|
1.4%
50th
|
| FCF margin, 3-yr average | 2.8%
70th
|
2.1%
50th
|
1.8%
40th
|
| Revenue stability (0-1) | 0.93
10th
|
0.98
70th
|
1.00
100th
|
| Earnings stability (0-1) | 0.21
40th
|
0.01
0th
|
0.24
50th
|
| Margin stability (0-1) | 0.90
80th
|
0.69
20th
|
0.90
70th
|
Liquidity (latest quarter)
7 measures| Measure | CI | ELV | CVS |
|---|---|---|---|
| Cash & short-term investments | $6.3B
30th
|
$37.5B
100th
|
$14.0B
60th
|
| Net cash (− = net debt) | −$25.6B
20th
|
$6.5B
70th
|
−$62.3B
0th
|
| Working capital | −$8.6B
20th
|
$34.4B
100th
|
−$11.7B
10th
|
| Current ratio | 0.85
10th
|
2.05
90th
|
0.87
20th
|
| Quick ratio | 0.74
20th
|
2.05
90th
|
0.66
0th
|
| Cash ratio (cash + ST investments / current liabilities) | 0.11
0th
|
1.14
90th
|
0.16
10th
|
| Defensive interval (days) | 584 days
60th
|
312 days
20th
|
393 days
30th
|
Leverage & solvency (latest quarter)
13 measures| Measure | CI | ELV | CVS |
|---|---|---|---|
| Total debt | $31.9B
80th
|
$31.0B
70th
|
$76.3B
100th
|
| Debt / equity | 0.75
70th
|
0.69
30th
|
0.96
90th
|
| Net debt / equity | 0.60
90th
|
−0.14
70th
|
0.78
100th
|
| Debt / assets | 20.3%
40th
|
24.6%
60th
|
30.1%
100th
|
| Debt / capital | 42.8%
70th
|
40.9%
30th
|
48.9%
90th
|
| Debt / EBITDA | 2.57
25th
|
3.76
50th
|
5.69
88th
|
| Net debt / EBITDA | 2.06
88th
|
−0.78
62nd
|
4.65
100th
|
| Interest coverage (EBIT / interest) | 7.1x
88th
|
6.2x
75th
|
2.9x
25th
|
| Cash interest coverage | 7.4x
62nd
|
6.6x
38th
|
4.8x
25th
|
| Debt payback (years of OCF) | 3.1 yrs
60th
|
4.2 yrs
70th
|
5.2 yrs
80th
|
| Liabilities / assets | 72.7%
60th
|
64.4%
20th
|
68.5%
50th
|
| IS credit model rating | BBB+ | A | BB |
| Implied credit spread (bps) | 225
70th
|
150
50th
|
475
100th
|
Efficiency
11 measures| Measure | CI | ELV | CVS |
|---|---|---|---|
| Asset turnover | 1.83
50th
|
1.62
10th
|
1.62
20th
|
| Fixed asset turnover | 75.58
56th
|
43.30
22nd
|
15.03
0th
|
| Inventory turnover | 42.2 | — | 20.3 |
| Receivables turnover | 9.1
10th
|
18.7
70th
|
18.6
60th
|
| Days sales outstanding | 40 days
90th
|
19 days
30th
|
20 days
40th
|
| Days inventory outstanding | 9 days | — | 18 days |
| Days payables outstanding | 36 days
70th
|
74 days
100th
|
18 days
20th
|
| Cash conversion cycle (days) | 12 days
60th
|
−54 days
0th
|
20 days
90th
|
| Capex / revenue | 0.4%
60th
|
0.6%
70th
|
0.7%
80th
|
| Capex / depreciation | 0.45
10th
|
0.92
70th
|
0.67
40th
|
| Operating expense ratio | 17.1%
80th
|
85.0%
90th
|
10.4%
40th
|
Cash flow & earnings quality
7 measures| Measure | CI | ELV | CVS |
|---|---|---|---|
| Operating cash flow / net income | 1.60
29th
|
1.50
14th
|
3.01
57th
|
| FCF / net income | 1.42
29th
|
1.27
14th
|
2.40
57th
|
| FCF / operating cash flow | 88.7%
60th
|
84.3%
30th
|
79.6%
20th
|
| Capex / operating cash flow | 11.3%
40th
|
15.7%
70th
|
20.4%
80th
|
| Accruals ratio | -2.5%
70th
|
-2.0%
90th
|
-3.9%
50th
|
| Sloan accruals ratio | 0.6%
40th
|
26.7%
90th
|
0.9%
50th
|
| Earnings quality score (0-1) | 1.00
57th
|
1.00
57th
|
1.00
57th
|
Scores & forensic checks
15 measures| Measure | CI | ELV | CVS |
|---|---|---|---|
| IS score | 61
70th
|
57
60th
|
52
40th
|
| IS profitability | 27
50th
|
38
80th
|
16
40th
|
| IS growth | 63
70th
|
39
20th
|
50
50th
|
| IS value | 74
100th
|
68
90th
|
52
70th
|
| IS momentum | 90
80th
|
69
40th
|
79
50th
|
| IS risk (safety) | 65
10th
|
80
50th
|
65
10th
|
| IS quality | 70
80th
|
69
70th
|
65
40th
|
| IS balance sheet | 48
20th
|
76
70th
|
36
0th
|
| IS earnings quality | 84
80th
|
84
90th
|
83
70th
|
| IS cash flow | 64
60th
|
58
40th
|
61
50th
|
| Piotroski F-score (0-9) | 8
80th
|
6
30th
|
8
80th
|
| Altman Z-score | 2.8
40th
|
3.1
50th
|
2.5
10th
|
| Beneish M-score | −2.82
50th
|
−2.71
70th
|
−2.71
60th
|
| Ohlson O-score | −7.59
50th
|
−8.43
10th
|
−7.94
30th
|
| IS credit score | 60
30th
|
74
50th
|
41
0th
|
Size (TTM)
8 measures| Measure | CI | ELV | CVS |
|---|---|---|---|
| Market cap | $79.9B
70th
|
$92.9B
80th
|
$118.1B
90th
|
| Revenue | $282.4B
80th
|
$201.1B
70th
|
$415.1B
90th
|
| EBITDA | $12.4B
80th
|
$8.3B
70th
|
$13.4B
90th
|
| Net income | $6.4B
90th
|
$5.0B
80th
|
$4.9B
70th
|
| Free cash flow | $9.1B
80th
|
$6.3B
60th
|
$11.8B
90th
|
| Total assets | $157.1B
80th
|
$126.4B
70th
|
$253.8B
90th
|
| Shareholders' equity | $42.6B
70th
|
$44.9B
80th
|
$79.7B
90th
|
| Employees | 66,685
60th
|
96,615
80th
|
259,500
90th
|
Price performance
9 measures| Measure | CI | ELV | CVS |
|---|---|---|---|
| 1 day | +1.2% | −0.1% | −0.2% |
| 1 week | +7.1% | +3.7% | +7.2% |
| 1 month | +9.6% | +3.3% | +2.3% |
| 3 months | +6.5% | +12.0% | −13.6% |
| 6 months | +8.6% | +32.5% | +20.5% |
| Year to date | +8.4% | +20.8% | +16.2% |
| 1 year | +3.3% | +23.1% | +15.4% |
| 3 years, cumulative | +7.1% | −2.2% | +41.1% |
| 5 years, cumulative | +59.1% | +17.5% | +26.3% |
Technicals
4 measures| Measure | CI | ELV | CVS |
|---|---|---|---|
| RSI 14 | 73.4 | 66.8 | 58.2 |
| From 52-week high | −2.3% | −1.9% | −16.0% |
| From 52-week low | +27.0% | +56.7% | +32.9% |
| Beta | 0.30 | 0.71 | 0.60 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17